metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population 6
mUC - L1 - PDL1 positive 2

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open